{"items": "50", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Genmab Announces Financial Results for the First Quarter of 2024", "url": "https://www.globenewswire.com/news-release/2024/05/02/2874427/0/en/Genmab-Announces-Financial-Results-for-the-First-Quarter-of-2024.html", "time_published": "20240502T150100", "authors": ["Genmab A/S"], "summary": "May 2, 2024 Copenhagen, Denmark. Interim Report for the First Quarter Ended March ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.156708, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.030524", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.15173", "ticker_sentiment_score": "0.110284", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.407844", "ticker_sentiment_score": "0.175143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.061003", "ticker_sentiment_score": "0.209114", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.030524", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "PDS Biotech Appoints Stephan Toutain as Chief Operating Officer", "url": "https://www.globenewswire.com/news-release/2024/05/02/2874120/37149/en/PDS-Biotech-Appoints-Stephan-Toutain-as-Chief-Operating-Officer.html", "time_published": "20240502T120000", "authors": ["PDS Biotechnology Corporation"], "summary": "Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/e2e7d124-dbd4-4140-9cc5-449d3488a902", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995973"}], "overall_sentiment_score": 0.176757, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.027351", "ticker_sentiment_score": "0.035637", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.027351", "ticker_sentiment_score": "0.035637", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDSB", "relevance_score": "0.136113", "ticker_sentiment_score": "0.061842", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVXL", "relevance_score": "0.027351", "ticker_sentiment_score": "0.035637", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.027351", "ticker_sentiment_score": "0.035637", "ticker_sentiment_label": "Neutral"}]}, {"title": "PDS Biotech Appoints Stephan Toutain as Chief Operating Officer - PDS Biotechnology  ( NASDAQ:PDSB ) ", "url": "https://www.benzinga.com/pressreleases/24/05/g38579999/pds-biotech-appoints-stephan-toutain-as-chief-operating-officer", "time_published": "20240502T120000", "authors": ["Globe Newswire"], "summary": "PRINCETON, N.J., May 02, 2024 ( GLOBE NEWSWIRE ) -- PDS Biotechnology Corporation PDSB ( \"PDS Biotech\" or the \"Company\" ) , a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.998333"}], "overall_sentiment_score": 0.176583, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.026127", "ticker_sentiment_score": "0.035383", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.026127", "ticker_sentiment_score": "0.035383", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDSB", "relevance_score": "0.155786", "ticker_sentiment_score": "0.066955", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVXL", "relevance_score": "0.026127", "ticker_sentiment_score": "0.035383", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.026127", "ticker_sentiment_score": "0.035383", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: What's Going On With Stock Market? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/news/earnings/24/05/38576979/nasdaq-s-p-500-futures-rise-ahead-of-apple-earnings-why-this-analyst-thinks-no-cut-scenario-may-not", "time_published": "20240502T105251", "authors": ["Shanthi Rexaline"], "summary": "U.S. stocks look to push ahead on a positive path, now that the Federal Reserve's rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/02/Wall-Street.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.081907, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.133655", "ticker_sentiment_score": "-0.055256", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.067064", "ticker_sentiment_score": "0.097849", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOVA", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PENN", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTGR", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "W", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLIC", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "X", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZTS", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYBR", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "Z", "relevance_score": "0.033562", "ticker_sentiment_score": "0.018657", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIVN", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ED", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNST", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICE", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGA", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KIM", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPEN", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGM", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "REG", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOLF", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QRVO", "relevance_score": "0.067064", "ticker_sentiment_score": "0.020026", "ticker_sentiment_label": "Neutral"}, {"ticker": "PXD", "relevance_score": "0.067064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.067064", "ticker_sentiment_score": "0.097849", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.067064", "ticker_sentiment_score": "0.029538", "ticker_sentiment_label": "Neutral"}]}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc.  ( NYSE American - DPSI ) , AdTheorent Holding Company, Inc.  ( Nasdaq - ADTH ) , Macatawa Bank Corporation  ( Nasdaq - MCBC ) , Shockwave Medical, Inc.  ( Nasdaq - SWAV ) ", "url": "https://www.benzinga.com/pressreleases/24/05/g38562905/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-decisionpoint", "time_published": "20240501T191453", "authors": ["Globe Newswire"], "summary": "BALA CYNWYD, Pa., May 01, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.94762"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.271165, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WTFC", "relevance_score": "0.138863", "ticker_sentiment_score": "0.224873", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCBC", "relevance_score": "0.069697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.20698", "ticker_sentiment_score": "0.062609", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.20698", "ticker_sentiment_score": "0.180248", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADTH", "relevance_score": "0.20698", "ticker_sentiment_score": "0.20418", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DPSIP", "relevance_score": "0.069697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.069697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going With Johnson & Johnson Stock On Wednesday? - Johnson & Johnson  ( NYSE:JNJ ) ", "url": "https://www.benzinga.com/general/biotech/24/05/38562078/johnson-johnson-wants-to-deal-with-talc-lawsuit-overhang-proposes-6-5b-settlement-package", "time_published": "20240501T184219", "authors": ["Vandana Singh"], "summary": "Wednesday, Johnson & Johnson JNJ announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ovarian cancer arising from cosmetic talc litigation.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/01/johnsons-5671315-1920.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.108081, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.616447", "ticker_sentiment_score": "-0.235221", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market", "url": "https://www.benzinga.com/pressreleases/24/05/g38561570/gene-therapies-in-degenerative-retinal-disease-hold-potential-to-capture-significant-portion-of-ma", "time_published": "20240501T181736", "authors": ["Globe Newswire"], "summary": "EXTON, PA, May 01, 2024 ( GLOBE NEWSWIRE ) -- In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus area for gene therapy investigation.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.286661, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADVM", "relevance_score": "0.050679", "ticker_sentiment_score": "0.188362", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RGNX", "relevance_score": "0.050679", "ticker_sentiment_score": "0.188362", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.050679", "ticker_sentiment_score": "0.188362", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "New to the Market - Life Sciences IPOs;  ( Nasdaq: MNDR )   ( NYSE: PACS )   ( Nasdaq: CTNM ) ", "url": "https://www.investorideas.com/news/2024/main/05011Stocks.asp", "time_published": "20240501T133826", "authors": [], "summary": "New to the Market - Life Sciences IPOs. ( Nasdaq: MNDR ) ( NYSE: PACS ...", "banner_image": null, "source": "Investor Ideas", "category_within_source": "n/a", "source_domain": "www.investorideas.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.967645"}], "overall_sentiment_score": 0.308232, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MNDR", "relevance_score": "0.04794", "ticker_sentiment_score": "0.179769", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACS", "relevance_score": "0.095707", "ticker_sentiment_score": "0.126221", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAMO", "relevance_score": "0.04794", "ticker_sentiment_score": "0.157769", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ULS", "relevance_score": "0.143131", "ticker_sentiment_score": "0.379904", "ticker_sentiment_label": "Bullish"}, {"ticker": "CTNM", "relevance_score": "0.04794", "ticker_sentiment_score": "0.056862", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.04794", "ticker_sentiment_score": "0.056862", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J advances $6.475 billion settlement of talc cancer lawsuits | Business", "url": "https://www.cnn.com/2024/05/01/business/j-and-j-talc-cancer-lawsuits-settlement/index.html", "time_published": "20240501T133600", "authors": [], "summary": "Johnson & Johnson moves forward with $6.475 billion settlement of talc cancer lawsuits ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1181904237.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.242776, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.149656", "ticker_sentiment_score": "-0.1448", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Forgotten Stock Advice That Delivers 170%+ Payout Growth", "url": "https://www.forbes.com/sites/brettowens/2024/05/01/the-forgotten-stock-advice-that-delivers-170-payout-growth/", "time_published": "20240501T131500", "authors": ["Brett Owens"], "summary": "One of the best ways to grab a dividend payer set to surge is a strategy you never hear about anymore: Pick up shares of a conglomerate. I know, I know. The word brings to mind \"old school\" companies like 3M ( MMM ) -which we discussed a couple weeks ago-and Honeywell International ( HON ) .", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/662ad1e985461e21e502532f/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.157727, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VLTO", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.457724", "ticker_sentiment_score": "0.258552", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.111834", "ticker_sentiment_score": "-0.017918", "ticker_sentiment_label": "Neutral"}]}, {"title": "Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics", "url": "https://www.globenewswire.com/news-release/2024/05/01/2873221/0/en/Samir-R-Patel-M-D-Appointed-Interim-CEO-for-Akari-Therapeutics.html", "time_published": "20240501T120100", "authors": ["Akari Therapeutics Plc"], "summary": "BOSTON and LONDON, May 01, 2024 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc ( Nasdaq: AKTX ) , a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/8d978f50-07a9-40a3-be69-45f51ccd94d9", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.997902"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.165176, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AKTX", "relevance_score": "0.105199", "ticker_sentiment_score": "0.149012", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURN", "relevance_score": "0.013188", "ticker_sentiment_score": "0.034002", "ticker_sentiment_label": "Neutral"}, {"ticker": "RZLT", "relevance_score": "0.013188", "ticker_sentiment_score": "0.024376", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.026372", "ticker_sentiment_score": "0.026929", "ticker_sentiment_label": "Neutral"}]}, {"title": "Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics - Akari Therapeutics  ( NASDAQ:AKTX ) , Peak Bio  ( OTC:PKBO ) ", "url": "https://www.benzinga.com/pressreleases/24/05/g38547749/samir-r-patel-m-d-appointed-interim-ceo-for-akari-therapeutics", "time_published": "20240501T120100", "authors": ["Globe Newswire"], "summary": "BOSTON and LONDON, May 01, 2024 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc AKTX, a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.998333"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.167436, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AKTX", "relevance_score": "0.10361", "ticker_sentiment_score": "0.147121", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURN", "relevance_score": "0.012987", "ticker_sentiment_score": "0.033928", "ticker_sentiment_label": "Neutral"}, {"ticker": "RZLT", "relevance_score": "0.012987", "ticker_sentiment_score": "0.024333", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.025971", "ticker_sentiment_score": "0.026861", "ticker_sentiment_label": "Neutral"}]}, {"title": "J&J subsidiary proposes paying about USD 6.48B over 25 years to settle talc lawsuits", "url": "https://www.business-standard.com/world-news/j-j-subsidiary-proposes-paying-about-usd-6-48b-over-25-years-to-settle-talc-lawsuits-124050100615_1.html", "time_published": "20240501T115446", "authors": ["AP"], "summary": "J&J subsidiary proposes paying $6.48 bn over 25 yrs to settle talc lawsuits Business Standard ...", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-05/02/full/1683045756-614.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.169448, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.19117", "ticker_sentiment_score": "-0.262193", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Stack Capital Invests $8 Million USD Into Canva", "url": "https://www.globenewswire.com/news-release/2024/05/01/2873118/0/en/Stack-Capital-Invests-8-Million-USD-Into-Canva.html", "time_published": "20240501T113000", "authors": ["Stack Capital Group Inc."], "summary": "Stack Capital is pleased to announce that it has invested US$8 million into Canva, a leading global online design platform.", "banner_image": "https://ml.globenewswire.com/Resource/Download/499cf09e-5b61-4521-bb8e-af6fd2b41157", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.308501, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.095138", "ticker_sentiment_score": "0.186381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNEJF", "relevance_score": "0.095138", "ticker_sentiment_score": "0.186381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RDDT", "relevance_score": "0.095138", "ticker_sentiment_score": "0.186381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SBUX", "relevance_score": "0.095138", "ticker_sentiment_score": "0.186381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.095138", "ticker_sentiment_score": "0.186381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STCGF", "relevance_score": "0.717937", "ticker_sentiment_score": "0.461161", "ticker_sentiment_label": "Bullish"}, {"ticker": "FDX", "relevance_score": "0.095138", "ticker_sentiment_score": "0.186381", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Did you take Covishield? Doctors advise against panic as AstraZeneca admits to rare side-effects", "url": "https://www.financialexpress.com/healthcare/covid-19/did-you-take-covishield-doctors-advise-against-panic-as-astrazeneca-admits-to-rare-side-effects/3474067/", "time_published": "20240501T110647", "authors": ["Sushmita Panda"], "summary": "British drugmaker AstraZeneca has admitted that its COVID-19 vaccine can cause a rare side effect of blood clotting and low platelet count after immunisation. The announcement caused panic among the people who took the COVID-19 jab.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/05/syringe-g7e75114dd_1920.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.083976, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.161928", "ticker_sentiment_score": "0.096388", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.032602", "ticker_sentiment_score": "-0.052377", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alkermes plc Reports First Quarter 2024 Financial Results", "url": "https://www.prnewswire.com/news-releases/alkermes-plc-reports-first-quarter-2024-financial-results-302132399.html", "time_published": "20240501T110000", "authors": ["Alkermes plc"], "summary": "- First Quarter Revenues of $350.4 Million - - GAAP Net Income from Continuing Operations of $38.9 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.23 - - Company Reiterates 2024 Financial Expectations -", "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.057285, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.544869", "ticker_sentiment_score": "-0.006722", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.024826", "ticker_sentiment_score": "-0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.024826", "ticker_sentiment_score": "-0.023078", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.", "url": "https://www.cnbc.com/2024/05/01/johnson-johnson-will-pay-6point5-billion-to-resolve-nearly-all-talc-ovarian-cancer-lawsuits-in-us.html", "time_published": "20240501T103153", "authors": ["Annika Kim Constantino"], "summary": "The deal would allow J&J to resolve the lawsuits through a third bankruptcy filing of a subsidiary company, LTL Management.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107363243-1706035367989-gettyimages-1480096596-0j5a5875_rjbkkqvw.jpeg?v=1714559291&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.303709, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.295867", "ticker_sentiment_score": "-0.458434", "ticker_sentiment_label": "Bearish"}]}, {"title": "3 No-Brainer Stocks to Buy With $200 Right Now", "url": "https://www.fool.com/investing/2024/05/01/3-no-brainer-stocks-to-buy-with-200-right-now/", "time_published": "20240501T092100", "authors": ["Sean Williams"], "summary": "You don't need a mountain of cash to grow your wealth on Wall Street.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F774971%2Ftwo-hundred-dollars-cash-money-invest-retire-stocks-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999767"}], "overall_sentiment_score": 0.258629, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FVRR", "relevance_score": "0.268458", "ticker_sentiment_score": "0.222913", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.210405", "ticker_sentiment_score": "0.093093", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca responds to Covishield vaccine concerns: Here's what they said", "url": "https://www.business-standard.com/health/astrazeneca-responds-to-covishield-vaccine-concerns-here-s-what-they-said-124050100180_1.html", "time_published": "20240501T051827", "authors": ["Vasudha Mukherjee"], "summary": "In response to growing concerns surrounding potential side effects linked to the AstraZeneca-Oxford Covid-19 vaccine, the pharmaceutical giant restated its dedication to patient safety.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2021-09/03/full/1630670072-8609.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.01956, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.504646", "ticker_sentiment_score": "0.068946", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.108466", "ticker_sentiment_score": "-0.07396", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns", "url": "https://www.business-standard.com/amp/health/astrazeneca-reaffirms-covid-vaccine-safety-amid-rare-side-effect-concerns-124050100053_1.html", "time_published": "20240501T020317", "authors": ["ANI"], "summary": "In light of recent concerns surrounding potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant has reiterated its commitment to patient safety while emphasising the vaccine's overall safety profile.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-04/29/thumb/fitandfill/400X400/1714409459-4744.jpg", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.012243, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.391311", "ticker_sentiment_score": "0.178844", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.081552", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns", "url": "https://www.business-standard.com/health/astrazeneca-reaffirms-covid-vaccine-safety-amid-rare-side-effect-concerns-124050100053_1.html", "time_published": "20240501T020317", "authors": ["ANI"], "summary": "AstraZeneca has made the admission in court documents in connection with a case that alleges that the vaccine, developed with the University of Oxford, caused death and serious injury in dozens of cases. ( Photo: Wikimedia Commons )", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-04/29/full/1714409459-4744.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.022023, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.43852", "ticker_sentiment_score": "0.057284", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.077094", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity - Johnson & Johnson  ( NYSE:JNJ ) ", "url": "https://www.benzinga.com/insights/options/24/04/38531452/spotlight-on-johnson-johnson-analyzing-the-surge-in-options-activity", "time_published": "20240430T184629", "authors": ["Benzinga Insights"], "summary": "Investors with a lot of money to spend have taken a bearish stance on Johnson & Johnson JNJ. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.157822, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.068306", "ticker_sentiment_score": "0.139515", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.068306", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.654246", "ticker_sentiment_score": "0.294472", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "EPA implements toughest restrictions yet on use of highly toxic chemical in paint stripper", "url": "https://www.cnn.com/2024/04/30/health/epa-methylene-chloride-paint-strippers/index.html", "time_published": "20240430T130028", "authors": ["Jen Christensen"], "summary": "The US Environmental Protection Agency finalized a rule Tuesday that will end many uses of the highly toxic, cancer-causing solvent methylene chloride. The chemical will still be available for certain purposes, but with new guidelines meant to keep workers safe.", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1392202076.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.084712, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.03319", "ticker_sentiment_score": "-0.064286", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.03319", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.03319", "ticker_sentiment_score": "-0.134419", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation - Johnson & Johnson  ( NYSE:JNJ ) , Cardio Diagnostics Hldgs  ( NASDAQ:CDIO ) ", "url": "https://www.benzinga.com/partner/health-care/24/04/38517052/3-trends-in-healthcare-guided-by-ai-and-the-companies-behind-the-innovation", "time_published": "20240430T120827", "authors": ["Jeremy Golden"], "summary": "Artificial intelligence ( AI ) is on the cusp of transforming nearly every single industry. When it comes to healthcare, several trends have emerged. As doctors and scientists continue to innovate, the market for AI in healthcare is expanding.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/30/Screenshot-2024-04-30-at-5-36-02PM.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.294133, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CDIO", "relevance_score": "0.084423", "ticker_sentiment_score": "0.168701", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MFCSF", "relevance_score": "0.028188", "ticker_sentiment_score": "0.024287", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.276179", "ticker_sentiment_score": "0.311727", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.140239", "ticker_sentiment_score": "0.070633", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's Covishield causes rare blood clot disorder TTS: What is it?", "url": "https://www.business-standard.com/companies/news/astrazeneca-s-covishield-causes-rare-blood-clot-disorder-tts-what-is-it-124043000340_1.html", "time_published": "20240430T070303", "authors": ["Nandini Singh"], "summary": "AstraZeneca, the company that makes the Covishield vaccine for Covid-19 pandemic, has admitted the inoculation has potential side effects.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-04/30/full/1714453725-4118.png?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.156041, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.570165", "ticker_sentiment_score": "-0.198773", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.062926", "ticker_sentiment_score": "0.013051", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Indian FMCG industry has been a driver contributing to India's economy, said Manish Anandani at IAA & ISA Retrospect and Prospects", "url": "https://www.financialexpress.com/business/brandwagon-the-indianfmcgindustryhas-been-a-driver-contributing-toindiaseconomy-said-manish-anandani-at-iaa-isa-retrospect-and-prospects-3472404/", "time_published": "20240430T060527", "authors": ["BrandWagon Online"], "summary": "The India Chapter of the International Advertising Association ( IAA ) in collaboration with The Indian Society of Advertisers ( ISA ) hosted the IAA and ISA Retrospect and Prospects with Manish Anandani, managing director - India, Kenvue ( erstwhile Johnson & Johnson Consumer Health ) on April ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/04/My-project-2024-04-30T113426.023.png", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.329582, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.330286", "ticker_sentiment_score": "0.27535", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.223866", "ticker_sentiment_score": "0.203751", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations", "url": "https://www.cnbc.com/2024/04/29/jj-bristol-myers-squibb-lose-medicare-drug-price-talks-challenges.html", "time_published": "20240429T222204", "authors": ["Annika Kim Constantino"], "summary": "The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107398685-1712674574391-gettyimages-1593997320-raa-johnsonj230812_npA3P.jpeg?v=1714427697&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.121913, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.087824", "ticker_sentiment_score": "-0.128057", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.174587", "ticker_sentiment_score": "-0.106315", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.087824", "ticker_sentiment_score": "-0.015857", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cutting Edge Picks: 3 Med Tech Stocks With Room to Run", "url": "https://markets.businessinsider.com/news/stocks/cutting-edge-picks-3-med-tech-stocks-with-room-to-run-1033302252", "time_published": "20240429T210742", "authors": ["Joey Frenette"], "summary": "Undoubtedly, investors seem to have a new appetite for next-level revenue growth. Generative AI, GLP-1 weight-loss drugs and other breakthrough innovations ( I'm not sure if the metaverse qualifies right now ) seek to expand in some pretty massive markets.", "banner_image": "https://investorplace.com/wp-content/uploads/2020/02/isrg-stock-300x169.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.295971, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALGN", "relevance_score": "0.106541", "ticker_sentiment_score": "0.117509", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.05339", "ticker_sentiment_score": "-0.017", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.159218", "ticker_sentiment_score": "0.153099", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Is a King of Dividend Safety", "url": "https://www.fool.com/investing/2024/04/29/johnson-johnson-is-a-king-of-dividend-safety/", "time_published": "20240429T142300", "authors": ["Matt DiLallo"], "summary": "The healthcare behemoth has fortified its dividend.", "banner_image": "https://media.ycharts.com/charts/5c2ee15090c73ff598de146acb419ed6.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.380671, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.062926", "ticker_sentiment_score": "0.184192", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWAV", "relevance_score": "0.062926", "ticker_sentiment_score": "0.173164", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.614836", "ticker_sentiment_score": "0.495553", "ticker_sentiment_label": "Bullish"}]}, {"title": "ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 - a First-in-Class Antiviral Innate Immunomodulator", "url": "https://www.benzinga.com/pressreleases/24/04/g38482503/ena-respiratory-announces-fda-ind-clearance-for-its-prophylactic-intranasal-inna-051-a-first-in-cl", "time_published": "20240429T080000", "authors": ["Globe Newswire"], "summary": "MELBOURNE, Australia, April 29, 2024 ( GLOBE NEWSWIRE ) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that the U.S.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.215658, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.056674", "ticker_sentiment_score": "0.133947", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Unusual Income ETFs That May Be Just What You're Looking For", "url": "https://www.fool.com/investing/2024/04/28/3-unusual-income-etfs-that-may-be-just-what-youre/", "time_published": "20240428T131500", "authors": ["James Brumley"], "summary": "They may be off the beaten path, but these exchange-traded funds just might meet your unique income need.", "banner_image": "https://g.foolcdn.com/editorial/images/774402/one-thousand-dollars-1000-fanned-out.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.218539, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.034039", "ticker_sentiment_score": "0.133002", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.034039", "ticker_sentiment_score": "0.154281", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.034039", "ticker_sentiment_score": "0.154281", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.034039", "ticker_sentiment_score": "0.154281", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Top Growth Stocks to Buy Right Now and Hold Forever", "url": "https://www.fool.com/investing/2024/04/28/2-top-growth-stocks-to-buy-now-and-hold-forever/", "time_published": "20240428T124500", "authors": ["Rachel Warren"], "summary": "These healthcare stocks can provide enviable long-term portfolio growth.", "banner_image": "https://g.foolcdn.com/editorial/images/773907/getty-couple-happy-in-kitchen.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.318166, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.043738", "ticker_sentiment_score": "0.142649", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.087344", "ticker_sentiment_score": "0.23405", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.043738", "ticker_sentiment_score": "0.195492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWAV", "relevance_score": "0.043738", "ticker_sentiment_score": "0.184503", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALPN", "relevance_score": "0.043738", "ticker_sentiment_score": "0.077297", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.216087", "ticker_sentiment_score": "0.249471", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Better Dividend Stock: AbbVie or Johnson & Johnson?", "url": "https://www.fool.com/investing/2024/04/28/better-dividend-stock-abbvie-or-johnson-johnson/", "time_published": "20240428T082000", "authors": ["Prosper Junior Bakiny"], "summary": "One thing is for sure: Dividend seekers can't go wrong with either.", "banner_image": "https://media.ycharts.com/charts/606ca6d7bad2ded63e4e23f32d1c43b2.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.215112, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.596349", "ticker_sentiment_score": "0.286691", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.051221", "ticker_sentiment_score": "0.025897", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.479385", "ticker_sentiment_score": "0.29997", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "NAMIWalks Greater LA County Mental Health Festival Taking Place at LA State Historic Park", "url": "https://www.benzinga.com/pressreleases/24/04/n38476927/namiwalks-greater-la-county-mental-health-festival-taking-place-at-la-state-historic-park", "time_published": "20240427T153000", "authors": ["PRNewswire"], "summary": "LOS ANGELES, April 27, 2024 /PRNewswire/ -- The National Alliance on Mental Illness Greater L.A. County ( NAMI GLAC ) will celebrate its 20th annual NAMIWalks Greater LA County Mental Health Festival during Mental Health Awareness Month on Saturday, May 4, 2024.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.300726, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.064973", "ticker_sentiment_score": "0.198444", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Johnson & Johnson Stock: Buy, Sell, or Hold?", "url": "https://www.fool.com/investing/2024/04/27/johnson-johnson-stock-buy-sell-or-hold/", "time_published": "20240427T114500", "authors": ["David Jagielski"], "summary": "Is this top healthcare stock worth adding to your portfolio today?", "banner_image": "https://g.foolcdn.com/editorial/images/773651/a-doctor-using-a-stethoscope.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.210394, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.330876", "ticker_sentiment_score": "0.124083", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie  ( ABBV )  Beats on Q1 Earnings & Sales, Ups '24 EPS View", "url": "https://www.zacks.com/stock/news/2263588/abbvie-abbv-beats-on-q1-earnings-sales-ups-24-eps-view", "time_published": "20240426T161000", "authors": ["Zacks Equity Research"], "summary": "AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998311"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.126215, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GMAB", "relevance_score": "0.112008", "ticker_sentiment_score": "0.281693", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.327366", "ticker_sentiment_score": "0.299765", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.074809", "ticker_sentiment_score": "0.063534", "ticker_sentiment_label": "Neutral"}]}, {"title": "Are You Looking for a High-Growth Dividend Stock?", "url": "https://www.zacks.com/stock/news/2263489/are-you-looking-for-a-high-growth-dividend-stock", "time_published": "20240426T154509", "authors": ["Zacks Equity Research"], "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default175.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}], "overall_sentiment_score": 0.421112, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.448316", "ticker_sentiment_score": "0.497143", "ticker_sentiment_label": "Bullish"}]}, {"title": "Stocks Rebound Amid Big-Cap Earnings: Weekly Review", "url": "https://www.investors.com/news/stock-market-rebounds-tesla-microsoft-google-meta-chipotle-ge-in-focus-weekly-review/", "time_published": "20240426T153400", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "Stock Market Rebounds. Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/02/VIDEO-IBDDIFF-NYSE-020819-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.022015, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.033075", "ticker_sentiment_score": "0.224841", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MXL", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.103259", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.001918", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.066093", "ticker_sentiment_score": "0.023298", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.098998", "ticker_sentiment_score": "-0.03743", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.060313", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.060313", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXN", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.103259", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.103259", "ticker_sentiment_label": "Neutral"}, {"ticker": "URI", "relevance_score": "0.049595", "ticker_sentiment_score": "0.079806", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.11539", "ticker_sentiment_score": "0.136118", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.14802", "ticker_sentiment_score": "-0.032445", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLX", "relevance_score": "0.033075", "ticker_sentiment_score": "0.022472", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.033075", "ticker_sentiment_score": "0.009549", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLO", "relevance_score": "0.033075", "ticker_sentiment_score": "0.022472", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRT", "relevance_score": "0.033075", "ticker_sentiment_score": "0.091842", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.066093", "ticker_sentiment_score": "0.103051", "ticker_sentiment_label": "Neutral"}, {"ticker": "GD", "relevance_score": "0.049595", "ticker_sentiment_score": "0.115876", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.082563", "ticker_sentiment_score": "0.139202", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.131733", "ticker_sentiment_score": "-0.001266", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUE", "relevance_score": "0.066093", "ticker_sentiment_score": "-0.074412", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.066093", "ticker_sentiment_score": "0.040467", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.131733", "ticker_sentiment_score": "0.004932", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.098998", "ticker_sentiment_score": "-0.003314", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOC", "relevance_score": "0.033075", "ticker_sentiment_score": "0.112318", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.033075", "ticker_sentiment_score": "0.159617", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GM", "relevance_score": "0.033075", "ticker_sentiment_score": "0.164521", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OII", "relevance_score": "0.049595", "ticker_sentiment_score": "0.023", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.000998", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMUS", "relevance_score": "0.049595", "ticker_sentiment_score": "-0.034001", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.033075", "ticker_sentiment_score": "0.159617", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAL", "relevance_score": "0.049595", "ticker_sentiment_score": "0.023", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.033075", "ticker_sentiment_score": "0.112318", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.000998", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.103259", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.082563", "ticker_sentiment_score": "0.097489", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.033075", "ticker_sentiment_score": "0.037093", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.033075", "ticker_sentiment_score": "0.022472", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.08357", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEV", "relevance_score": "0.066093", "ticker_sentiment_score": "-0.049623", "ticker_sentiment_label": "Neutral"}, {"ticker": "PI", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.103259", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTI", "relevance_score": "0.049595", "ticker_sentiment_score": "0.023", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLF", "relevance_score": "0.049595", "ticker_sentiment_score": "-0.073841", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.082563", "ticker_sentiment_score": "-0.044057", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.033075", "ticker_sentiment_score": "-0.000998", "ticker_sentiment_label": "Neutral"}, {"ticker": "STLD", "relevance_score": "0.049595", "ticker_sentiment_score": "-0.073841", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Stocks in Focus on Their Recent Dividend Hike", "url": "https://www.zacks.com/stock/news/2263132/5-stocks-in-focus-on-their-recent-dividend-hike", "time_published": "20240426T121300", "authors": ["Nalak Das"], "summary": "Five stocks to focus with recent dividend hike are: JNJ, TRV, SON, KBH, SPFI.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1948.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.195152, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KBH", "relevance_score": "0.369319", "ticker_sentiment_score": "0.166401", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRV", "relevance_score": "0.369319", "ticker_sentiment_score": "0.480674", "ticker_sentiment_label": "Bullish"}, {"ticker": "SON", "relevance_score": "0.299478", "ticker_sentiment_score": "0.212312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTBK", "relevance_score": "0.038345", "ticker_sentiment_score": "0.061439", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPFI", "relevance_score": "0.334762", "ticker_sentiment_score": "0.144375", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.299478", "ticker_sentiment_score": "0.251639", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - Cidara Therapeutics  ( NASDAQ:CDTX ) ", "url": "https://www.benzinga.com/pressreleases/24/04/g38457396/cidara-therapeutics-announces-presentations-highlighting-phase-1-and-phase-2a-clinical-data-on-cd3", "time_published": "20240426T120000", "authors": ["Globe Newswire"], "summary": "SAN DIEGO, April 26, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.155306, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CDTX", "relevance_score": "0.212425", "ticker_sentiment_score": "0.155088", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.07157", "ticker_sentiment_score": "0.073387", "ticker_sentiment_label": "Neutral"}]}, {"title": "BioNJ Announces Lineup for BioPartnering Conference", "url": "https://www.prnewswire.com/news-releases/bionj-announces-lineup-for-biopartnering-conference-302127910.html", "time_published": "20240425T182700", "authors": ["BioNJ"], "summary": "TRENTON, N.J., April 25, 2024 /PRNewswire/ -- BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City. Sponsored by J.P.", "banner_image": "https://mma.prnewswire.com/media/2397912/BioNJ_BioPartnering_Conference_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.380824, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.097854", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.194242", "ticker_sentiment_score": "0.073971", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.097854", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Monthly Depth Report: The Blind Leading The Confused - Shockwave Medical  ( NASDAQ:SWAV ) ", "url": "https://www.benzinga.com/opinion/24/04/38437069/monthly-depth-report-the-blind-leading-the-confused", "time_published": "20240425T155927", "authors": ["Gary Brode"], "summary": "One of the best experiences I've had in my investment career was being partner and co portfolio manager with Raji Khabbaz. He's a fantastic stock-picker and the two of us spent the better part of a decade discussing and debating investment ideas.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/25/nicholas-cappello-wb63zqj5gne-unsplash_1.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999986"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.07264, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SWAV", "relevance_score": "0.028338", "ticker_sentiment_score": "0.085825", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.028338", "ticker_sentiment_score": "0.085825", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here Are My Top 5 Dividend Kings to Buy Right Now", "url": "https://www.fool.com/investing/2024/04/25/here-are-my-top-5-dividend-kings-to-buy-right-now/", "time_published": "20240425T131500", "authors": ["Adam Spatacco"], "summary": "Dividend Kings are hard to come by, but these five stocks offer investors some great passive income opportunities.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773701%2Fcopy-of-dividends-blackboard-sketch-doodle.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.319823, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.137083", "ticker_sentiment_score": "0.13966", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOLV", "relevance_score": "0.03443", "ticker_sentiment_score": "0.190962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MO", "relevance_score": "0.237469", "ticker_sentiment_score": "0.227408", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KO", "relevance_score": "0.103035", "ticker_sentiment_score": "0.270812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.068797", "ticker_sentiment_score": "0.145609", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.237469", "ticker_sentiment_score": "0.19416", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher", "url": "https://www.fool.com/investing/2024/04/25/this-small-cap-stock-is-up-150-this-year-and-heres/", "time_published": "20240425T093700", "authors": ["David Jagielski"], "summary": "For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.", "banner_image": "https://media.ycharts.com/charts/887c4d12055417c81c6d752c80b64f41.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.28068, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MNMD", "relevance_score": "0.575728", "ticker_sentiment_score": "0.317542", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.057907", "ticker_sentiment_score": "0.127985", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pre-Investor Call Presentation available to shareholders", "url": "https://www.globenewswire.com/news-release/2024/04/25/2869320/0/en/Pre-Investor-Call-Presentation-available-to-shareholders.html", "time_published": "20240425T064000", "authors": ["VIRTUALWARE 2007 SA"], "summary": "Investors can access and view today's presentation materials by following this link: Headquartered in Bilbao, Spain, Virtualware is a global pioneer in developing virtual reality solutions for large industrial, educational, and healthcare conglomerates.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/6aee44c0-62ac-4f66-9be0-b3578d202005", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.20415, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GEV", "relevance_score": "0.073773", "ticker_sentiment_score": "0.119019", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBDSF", "relevance_score": "0.073773", "ticker_sentiment_score": "0.119019", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOMFF", "relevance_score": "0.073773", "ticker_sentiment_score": "0.119019", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.073773", "ticker_sentiment_score": "0.119019", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.073773", "ticker_sentiment_score": "0.119019", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investing in Cardiovascular MedTech Companies", "url": "https://investingnews.com/investing-in-cardiovascular-medtech-companies/", "time_published": "20240424T224704", "authors": ["Investing News Network"], "summary": "Efforts to address the core risk factors associated with cardiovascular diseases are coinciding with recent innovations in medical technology, which have been critical in not only preventing and managing them but also increasing the survival rate.", "banner_image": "https://investingnews.com/media-library/illustration-of-heart-attack.png?id=52093924&width=1200&height=800&quality=85&coordinates=0%2C0%2C0%2C0", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.426531, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CDEXF", "relevance_score": "0.101725", "ticker_sentiment_score": "0.094903", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.101725", "ticker_sentiment_score": "0.089634", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.03399", "ticker_sentiment_score": "0.205849", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.101725", "ticker_sentiment_score": "0.089634", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.03399", "ticker_sentiment_score": "0.084292", "ticker_sentiment_label": "Neutral"}]}, {"title": "NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results", "url": "https://www.globenewswire.com/news-release/2024/04/24/2869144/0/en/NANOBIOTIX-Provides-Business-Update-and-Reports-Full-Year-2023-Financial-Results.html", "time_published": "20240424T204000", "authors": ["Nanobiotix S.A."], "summary": "Conference call and webcast scheduled for April 25, 2024 at 8:00 A.M. EDT / 2:00 P.M. CEST ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}], "overall_sentiment_score": 0.116494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NBTX", "relevance_score": "0.298749", "ticker_sentiment_score": "0.101264", "ticker_sentiment_label": "Neutral"}, {"ticker": "LIANY", "relevance_score": "0.015304", "ticker_sentiment_score": "0.082886", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.030602", "ticker_sentiment_score": "0.075618", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.015304", "ticker_sentiment_score": "0.047629", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's a rapid-fire update on all 33 portfolio stocks including our tech giants reporting this week", "url": "https://www.cnbc.com/2024/04/24/jim-cramers-rapid-fire-update-on-all-33-investing-club-stocks.html", "time_published": "20240424T195309", "authors": ["Kevin Stankiewicz", "Morgan Chittum"], "summary": "During the Investing Club's Monthly Meeting on Wednesday, Jim Cramer offered his updated thinking on the stocks in the portfolio.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107381791-1709565572170-gettyimages-2050810312-AFP_34KQ4DT.jpeg?v=1713980195&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.999974"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.147834, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DD", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "VMW", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFA", "relevance_score": "0.028473", "ticker_sentiment_score": "0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "FL", "relevance_score": "0.042698", "ticker_sentiment_score": "0.061498", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.05691", "ticker_sentiment_score": "0.062053", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.042698", "ticker_sentiment_score": "0.061498", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.042698", "ticker_sentiment_score": "0.061498", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBY", "relevance_score": "0.042698", "ticker_sentiment_score": "0.061498", "ticker_sentiment_label": "Neutral"}, {"ticker": "STZ", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.042698", "ticker_sentiment_score": "0.061498", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.028473", "ticker_sentiment_score": "0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.028473", "ticker_sentiment_score": "0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "TJX", "relevance_score": "0.028473", "ticker_sentiment_score": "0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.042698", "ticker_sentiment_score": "0.061498", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.028473", "ticker_sentiment_score": "0.058975", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWK", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTRA", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.014239", "ticker_sentiment_score": "0.054481", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vanda  ( VNDA )  to Report Q1 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2261585/vanda-vnda-to-report-q1-earnings-whats-in-the-cards", "time_published": "20240424T175800", "authors": ["Zacks Equity Research"], "summary": "On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.109272, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CTMX", "relevance_score": "0.190793", "ticker_sentiment_score": "-0.003041", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.048133", "ticker_sentiment_score": "-0.071085", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.1437", "ticker_sentiment_score": "0.171113", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VNDA", "relevance_score": "0.327366", "ticker_sentiment_score": "0.028564", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.1437", "ticker_sentiment_score": "0.159788", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?", "url": "https://www.zacks.com/stock/news/2261011/whats-in-store-for-these-5-pharma-bigwigs-in-q1-earnings", "time_published": "20240424T131900", "authors": ["Ahan Chakraborty"], "summary": "Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/58479.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.154863, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.039614", "ticker_sentiment_score": "-0.008857", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.039614", "ticker_sentiment_score": "-0.080241", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.039614", "ticker_sentiment_score": "0.342197", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.234307", "ticker_sentiment_score": "0.134722", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.196132", "ticker_sentiment_score": "-0.010985", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.118452", "ticker_sentiment_score": "0.061763", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.196132", "ticker_sentiment_score": "0.04485", "ticker_sentiment_label": "Neutral"}]}]}